Veronique W.T. Ruiz van Haperen

2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Jan B. Vermorken et al. · Biochemical Pharmacology · 1993 · 254 citations

Medicine, Molecular Biology, Oncology +10

<i>In vivo</i> Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant

Andries M. Bergman, Paul P. Eijk, Veronique W.T. Ruiz van Haperen et al. · Cancer Research · 2005 · 181 citations · Full text

Medicine, Oncology, Pharmacology +15

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, S. Eriksson et al. · PubMed · 1994 · 168 citations

Medicine, Oncology, Pharmacology +16

Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

Boudewijn J.M. Braakhuis, Veronique W.T. Ruiz van Haperen, E. Boven et al. · PubMed · 1995 · 141 citations

Medicine, Oncology, Pharmacology +14

Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Epie Boven et al. · Biochemical Pharmacology · 1994 · 125 citations

Medicine, Oncology, Pharmacology +16